Open AccessNew‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
Author(s) -
Guida Agostino,
Perri Francesco,
Ionna Franco,
Ascierto Paolo A.,
Grimaldi Antonio M.
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3418
Subject(s) - medicine , osteonecrosis of the jaw , ipilimumab , multidisciplinary team , chemotherapy , immunotherapy , dermatology , surgery , bisphosphonate , cancer , osteoporosis , nursing
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom